Caris Life Sciences, Inc.
CAI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $7 | $7 | $7 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $2 |
| Enterprise Value | $7 | $7 | $7 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 34.7% | 18.4% | -12.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 43.4% | 29.2% | 31% | 62.6% |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | -44.4% | -85.2% | -95.1% | 86.5% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -68.4% | -111.5% | -124.1% | 9.4% |
| EPS Diluted | -2.7 | -1.82 | -1.57 | 1.55 |
| % Growth | -48.4% | -15.9% | -201.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |